The Growing Market for Recurrent Pericarditis Therapies

Recurrent pericarditis management has evolved significantly in recent years, with treatment approaches…

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Toronto, Ontario–(Newsfile Corp. – April 16, 2025) – Cardiol Therapeutics Inc. (NASDAQ: CRDL)…

From $1 to $8? Why Analyst Experts Are Bullish on Cardiol

Sometimes stock market performance doesn’t line up with the fundamentals of a…

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology

Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug…

These Healthcare Stocks Significantly Outperformed the Industry in 2024

While the stock market broadly experienced significant gains in 2024, a few…

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Administration of CardiolRx™ led to a marked reduction in the primary efficacy…